• head_banner_01

OEM Manufacturer Rhodium(Iii) Nitrate 10139-58-9 - Ganirelix Acetate Peptide API – Gentolex

Short Description:


Product Detail

Product Tags

Related Video

Feedback (2)

Our development depends on the advanced equipment, excellent talents and continuously strengthened technology forces for Organic Malic Acid, N-(3-Aminopropyl)-Imidazole, Brigatinib, Welcome your visiting and any your inquires,sincerely hope we can have chance to cooperate with you and we can build up long well business relationship with you.
OEM Manufacturer Rhodium(Iii) Nitrate 10139-58-9 - Ganirelix Acetate Peptide API – Gentolex Detail:

Product Detail

Name  Ganirelix Acetate
CAS number  123246-29-7
Molecular formula  C80H113ClN18O13
Molecular weight  1570.34

Synonyms

Ac-DNal-DCpa-DPal-Ser-Tyr-DHar(Et2)-Leu-Har(Et2)-Pro-DAla -NH2;Ganirelixum;ganirelix Acetate; GANIRELIX; Ganirelix Acetate USP/EP/

Description

Ganirelix is a synthetic decapeptide compound, and its acetate salt, Ganirelix acetate is a gonadotropin-releasing hormone (GnRH) receptor antagonist. The amino acid sequence is: Ac-D-2Nal-D-4Cpa-D-3Pal-Ser-Tyr-D-HomoArg(9,10-Et2)-Leu-L-HomoArg(9,10-Et2)-Pro-D- Ala-NH2. Mainly clinically, it is used in women undergoing assisted reproductive technology controlled ovarian stimulation programs to prevent premature luteinizing hormone peaks and to treat fertility disorders due to this cause. The drug has the characteristics of less adverse reactions, high pregnancy rate and short treatment period, and has obvious advantages compared with similar drugs in clinical practice.

Pharmacological Action

The pulsatile release of gonadotropin-releasing hormone (GnRH) stimulates the synthesis and secretion of LH and FSH. The frequency of LH pulses in the mid and late follicular phases is approximately 1 per hour. These pulses are reflected in transient rises in serum LH. During mid-menstrual period, the massive release of GnRH causes a surge of LH. The midmenstrual LH surge can trigger several physiological responses, including: ovulation, oocyte meiotic resumption, and corpus luteum formation. The formation of the corpus luteum causes serum progesterone levels to rise, while estradiol levels fall. Ganirelix acetate is a GnRH antagonist that competitively blocks GnRH receptors on pituitary gonadotrophs and subsequent transduction pathways. It produces a rapid, reversible inhibition of gonadotropin secretion. The inhibitory effect of ganirelix acetate on pituitary LH secretion was stronger than that on FSH. Ganirelix acetate failed to induce the first release of endogenous gonadotropins, consistent with antagonism. Complete recovery of pituitary LH and FSH levels occurred within 48 hours after ganirelix acetate was discontinued.


Product detail pictures:

OEM Manufacturer Rhodium(Iii) Nitrate 10139-58-9 - Ganirelix Acetate Peptide API – Gentolex detail pictures

OEM Manufacturer Rhodium(Iii) Nitrate 10139-58-9 - Ganirelix Acetate Peptide API – Gentolex detail pictures


Related Product Guide:

We depend on sturdy technical force and continually create sophisticated technologies to meet the demand of OEM Manufacturer Rhodium(Iii) Nitrate 10139-58-9 - Ganirelix Acetate Peptide API – Gentolex , The product will supply to all over the world, such as: Mozambique, Florence, Florida, If you give us a list of merchandise you are interested in, along with makes and models, we can send you quotations. Remember to email us directly. Our goal is to establish long-term and mutually profitable business relationships with domestic and overseas clients. We look forward to receiving your reply soon.
  • This company has the idea of "better quality, lower processing costs, prices are more reasonable", so they have competitive product quality and price, that's the main reason we chose to cooperate.
    5 Stars By Delia from Barbados - 2018.12.05 13:53
    The company has rich resources, advanced machinery, experienced workers and excellent services, hope you keep improving and perfecting your products and service, wish you better!
    5 Stars By Lesley from Turkmenistan - 2018.06.18 19:26
    Write your message here and send it to us